282 related articles for article (PubMed ID: 22781459)
1. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
Li X; Sun WJ; Chen SL; Zhong YP; An N; Hu Y; Zhang JJ; Liu XH
Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(12):838-41. PubMed ID: 22781459
[TBL] [Abstract][Full Text] [Related]
2. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
Zhong YP; Chen SL
Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158
[TBL] [Abstract][Full Text] [Related]
3. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
Hughes M; Micallef-Eynaud P
Clin Lab Haematol; 2006 Aug; 28(4):267-9. PubMed ID: 16898968
[TBL] [Abstract][Full Text] [Related]
5. Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
Fukushima T; Nakamura T; Miki M; Sakai T; Iwao H; Nakajima A; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Hirose Y; Umehara H
Anticancer Res; 2010 Sep; 30(9):3791-4. PubMed ID: 20944171
[TBL] [Abstract][Full Text] [Related]
6. Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal.
Zhang J; Zhong Y
Hematol Oncol; 2015 Jun; 33(2):75-9. PubMed ID: 24395149
[TBL] [Abstract][Full Text] [Related]
7. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
8. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
Liang Z; Ren H; Cen X; Li Y; Wang L; Ou J; Dong Y; Yin Y; Wang W; Liu W; Wang Q; Qiu Z; Wang M; Xu W; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):225-30. PubMed ID: 24666489
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
11. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
12. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
13. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
[TBL] [Abstract][Full Text] [Related]
16. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
17. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
SAWADA T; NAJIMA Y; OHASHI K; KATO I; MIYAZAWA M; NAKANO M; KOBAYASHI T; YAMASHITA T; AKIYAMA H; SAKAMAKI H
Rinsho Ketsueki; 2009 Nov; 50(11):1635-40. PubMed ID: 20009440
[TBL] [Abstract][Full Text] [Related]
19. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]